INTRODUCTION
============

People with a human immune virus/acquired immune deficiency syndrome (HIV/AIDS) undergoing highly active antiretroviral therapy (HAART) often present with problems associated with HIV infection and its therapy ([@b28-jer-14-5-891]). These include metabolic changes, body and metabolic modifications, the stigma often associated with AIDS, chronic use of antiretroviral, and fear of imminent death. These problems taken together can affect the physical, social, and psychological health components, causing a negative impact on their quality of life (QoL) ([@b28-jer-14-5-891]). The increased number of people with HIV/AIDS increases the responsibility on the health care system, this shows the increased need to reduce disability level and improve optimal functional status of people living with HIV/AIDS so as to improve their QoL ([@b3-jer-14-5-891]). Exercise is consistently listed among the three most common complementary and alternative therapies utilized by HIV-infected persons to improve their QoL ([@b7-jer-14-5-891]; [@b13-jer-14-5-891]; [@b33-jer-14-5-891]; [@b34-jer-14-5-891]). Therapeutic exercise among people with HIV has been shown to be both beneficial and safe ([@b8-jer-14-5-891]).

The introduction of HAART has led to AIDS becoming a chronic disease, requiring nonphar-macological treatment methods such as therapeutic exercises ([@b27-jer-14-5-891]; [@b31-jer-14-5-891]) which maintains functionality and QoL for several years ([@b12-jer-14-5-891]). Therefore, maintaining the physical and functional fitness of patients with HIV/AIDS has become one of the most important therapeutic targets, particularly in the case of "wasting syndrome," which is an important loss of muscle mass ([@b32-jer-14-5-891]). Some studies have shown that the use of aerobic exercise ([@b28-jer-14-5-891]), as well as combined (aerobic and strength) exercise ([@b31-jer-14-5-891]) training has brought improvement in the aerobic capacity/functional capacity, body composition, metabolic indices, and QoL of patients with HIV.

Evidence has shown that engaging in physical activity regularly may improve mental health. ([@b12-jer-14-5-891]). Therefore, engaging in regular exercise is a valid method of managing the psychological manifestations of HIV infection ([@b12-jer-14-5-891]). Previous studies shows that participation in aerobic or strength training programme may lead to improvement in emotional, mental and physical well-being ([@b20-jer-14-5-891]), and reduction of depressive symptoms ([@b26-jer-14-5-891]), thus improving their QoL.

People infected with HIV have shown low aerobic capacities, manifested as reduced ability to utilize oxygen (maximum oxygen uptake, VO~2max~) and perform physical work ([@b19-jer-14-5-891]). People living with HIV have VO~2max~ of 24%--44% lower than their age-matched normal values during aerobic capacity functional test ability to utilize oxygen ([@b20-jer-14-5-891]; [@b21-jer-14-5-891]). While it is possible that the aetiology of this lowered work capacity is multifactorial, the available limited evidence suggests that moderate to high intensity aerobic exercise training is effective in improving the functional aerobic capacity of HIV-positive persons ([@b14-jer-14-5-891]).

Hypertension is found in around 25% of people with HIV because of sedentary lifestyles and other increased cardiovascular risk factors ([@b4-jer-14-5-891]; [@b22-jer-14-5-891]). The current recommendation for the treatment of hypertension in HIV patients is the same as in the normal population: lifestyle modifications, including regular exercise, are prescribed with the possible addition of anti-hypertensive drugs if needed ([@b4-jer-14-5-891]).

Unfortunately, treating HIV with HAART results in a number of physical and psychological adverse effects. Common physical adverse effects include disorders of the nervous system (headache, neuropathic pain, and fatigue), gastrointestinal tract (diarrhea, vomiting, and nausea), morphology (lipodystrophy and lipidatrophy), integumentary system (dry skin and rash), and metabolic processes (glucose, altered lipid profile, osteoporosis) ([@b15-jer-14-5-891]). Possible psychological side effects include agitation, confusion, anxiety, hallucinations, mania and depression ([@b16-jer-14-5-891]). Even though HAART reduces the mortality rate in HIV-individuals, the prolongation of patient's life can be accompanied with a reduction in their QoL ([@b8-jer-14-5-891]). Therefore, it becomes very necessary to develop protocols or treatment models which aim at enhancing QoL in HIV population.

Hence this study aims to evaluate the aerobic exercise programme effects on the cardiovascular indices, QoL, and body composition of people living with HIV.

MATERIALS AND METHODS
=====================

Research design
---------------

The study is a pretest-posttest controlled randomized design.

Subject selection
-----------------

A total of 60 subjects were recruited from the AIDS Prevention and Intervention Initiative clinic of a teaching hospital ([Fig. 1](#f1-jer-14-5-891){ref-type="fig"}) Subjects were consecutively invited to enter the protocol. They were randomly assigned to either experimental or control group. Simple random sampling using fish bowl method where numbers were written on cards and draws were made was used. Inclusion criteria were subjects currently on Active Retroviral drugs, age 18 years and above, availability to attend the study activities. Exclusion criteria were pregnant subjects, subjects contra indicated to exercise testing and training ([@b1-jer-14-5-891]), significant cognitive impairment, involvement in a regular exercise program (defined as two or more structured exercise sessions weekly for more than, or equal to 6 months prior to enrollment).

Instrumentation
---------------

### Medical outcomes study HIV health survey (MOS-HIV health survey)

The MOS-HIV survey (English version) was used to assess aspects of health-related QoL ([@b36-jer-14-5-891]). It has a good reliability and validity in populations with HIV ([@b6-jer-14-5-891]). The questionnaire consists of 35 items. It covers 10 dimensions of health and one item covering health transition. Subscales are scored as a summated rating on a 0--100 scale with a higher score representing better health-related QoL. The questionnaire was administered to all the subjects at baseline and at the sixth week.

### American Heart Association -- American College of Sports Medicine preparticipation screening questionnaire

This was developed by the [@b2-jer-14-5-891], to screen for cardiovascular risk factors and readiness to exercise before the individual commences an exercise programme. The questionnaire contains three sections. Section one assesses for history of cardiovascular disease, section two assesses for symptoms, section three assesses for cardiovascular risk factors. The experimental group was screened with this instrument before starting the exercise regimen.

### Treadmill exercise

A motor driven treadmill ergometer (KL001, Daily Youth Sports Product Co., Ltd., Guangzhou, China) was used to exercise the subjects.

### Tape rule

A nonelastic tape measure (HD2020, Sanghai Kearing Stationary Co., Ltd., Shanghi, China) of range 0--150 cm was used to measure the waist circumference (WC).

### Body composition monitor

An OMRON body composition monitor (BF 511, Daily Youth Sports Product Co., Ltd.) was used to measure the body composition. OMRON BF511 consists of the main unit and the display unit. The main unit has two pairs of foot electrodes while the display unit has two pairs of grip electrodes for the hands, a display screen and display buttons. A cord connects the display unit to the main unit. The OMRON BF511 measures the body fat (BF) percentage by the bioelectrical impedance (BI) method. It measures the following body composition parameters: BF (in %), visceral fat (VF) (up to 30 levels), body mass index (BMI) and skeletal muscle (in %)

### Height meter

A standiometer was used to measure subject's height in meter.

### Sphygmomanometer and stethoscope

This was used to measure systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate (HR).

Procedure
---------

An ethical approval was obtained from the institutional Research and Ethics Committee (Ref No.: ADM/DCST/HREC/VOL.XVI/APP/452). An informed consent form was also obtained from the subjects prior to participation.

### Body composition

Height was measured in meter (m) using a standiometer with subjects barefoot. Weight (kg) was measured using OMRON BF511, with the subject stepping on the main unit barefooted and placing the feet on the foot electrodes with the weight evenly distributed in an upright position. BMI was measured with OMRON BF511 which uses the height information stored in the personal profile or when entering the guest mode and weight measurement to calculate the BMI (kg/m^2^). The device uses the BI to estimate the BF percentage and VF percentage In order for the scale to determine body composition, it uses the electrical impedance, along with height, weight, age and gender information to generate results based on OMRON's data of body composition. The device also calculates the body skeletal muscle mass. WC in centimeter was measured at the level of the navel at the end of gentle expiration, with the subject in an upright position, measure with a flexible tape extendable to one decimal place ([@b17-jer-14-5-891]). The values were taken at baseline and at 6 weeks. All measurement was taken by one researcher to avoid inter rater error.

### Exercise training

Subjects were grouped into 5--8 subjects for ease of supervision by the researchers and were screened for cardiovascular risk factors. After being certified fit for exercise, the baseline blood pressure and HR was taken.

Aerobic exercise training was performed on a motor driven treadmill ergometer using a ramp protocol. Exercise was performed 3 times per week at a moderate intensity level for maximum of 45 min. Exercise was started with initial brisk walking pace, ranging from 1.5--2.0 mph at a 0% grade for 4 min to raise the HR within 40%--50% of predicted age maximum (220-age) ([@b1-jer-14-5-891]). This was followed by a second 4-min stage, retaining the same speed, but the treadmill was raised to a 5% grade. The speed was increased as the training progresses until the target HR 75% of the predicted maximum was reached. Exercise was monitored using Borg Perceived Rate of Exertion Scale. Participants were instructed to rate their perceived exertion ([@b5-jer-14-5-891]). Measurement of blood pressure and HR were taken every 3 min as an additional monitor. The VO~2max~ was calculated using the equation:
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Treadmill speed in mph; gender=0 for females, 1 for males ([@b1-jer-14-5-891]; [@b10-jer-14-5-891]). Measurement of resting HR and blood pressure were also taken. All the parameters were measured at baseline and 6 weeks.

### Quality of life

HIV-MOS health survey was used to measure the domains of QoL at baseline and at 6 weeks. The scoring of the subscales was done as a summated rating on a standardized scale of 0--100.

Data analysis
-------------

Descriptive statistics of mean, standard deviation and percentages was used to summarize data. Shapiro--Wilk *W*-test was used to test and confirm that the data was normally distributed. Unpaired *t*-test was used to compare the mean differences of variables between the groups. The differences between mean values were expressed at a confidence interval of 95%. All survey data were analyzed by using SPSS ver. 16.0 (SPSS Inc., Chicago, IL, USA).

RESULTS
=======

A total of 60 subjects were randomized (30 in each group). After randomization, 5 subjects dropped out of the experimental group without reaching 70% percent of completion. Three subjects dropped out of control group. All parameters were taken at baseline and at sixth week. All result were analyzed using a confidence interval of 95% and *P*\<0.05. [Table 1](#t1-jer-14-5-891){ref-type="table"} summarized the demographic characteristics of both the control and experimental group.

Between group comparison at 6 weeks shows that a significant difference exists in SBP, DBP, and resting HR at (*P*=0.001) ([Table 2](#t2-jer-14-5-891){ref-type="table"}). However, within group comparison ([Table 3](#t3-jer-14-5-891){ref-type="table"}) showed a significant difference in SBP, DBP, and resting HR (*P*=0.001) in the experimental group. Post intervention comparison between the groups shows that a significant difference exists in all the parameters: BMI, BF, VF, WC, muscle mass at *P*=0.002, *P*=0.042, *P*= 0.001, *P*=0.002, and *P*=0.001, respectively ([Table 4](#t4-jer-14-5-891){ref-type="table"}). In the experimental group, there was a significant difference in all the body composition parameters except VF at *P*=0.001 ([Table 5](#t5-jer-14-5-891){ref-type="table"}). A significant difference was attained in all the QoL domains after the intervention period at *P*=0.001 ([Table 6](#t6-jer-14-5-891){ref-type="table"}). There was also a significant difference in within group comparison of all the measured QoL life domains in both the control and experimental group ([Table 7](#t7-jer-14-5-891){ref-type="table"}).

DISCUSSION
==========

The study showed that a 6-week aerobic exercise intervention in HIV subjects can lead to an appreciable improvement in cardiovascular parameters, body composition and QoL.

The study demonstrated a 16% drop-out rate, which is less than the findings of a meta-analysis on aerobic exercise and HIV/AIDS, in which six studies reported drop-out rates higher than 20% and two others higher than 50% ([@b27-jer-14-5-891]). The observed lower dropout rate may be as a result of the constant text messages sent to the subjects reminding them of the importance to attend the exercise and nutritional counseling sessions. The subjects were also given some stipends.

However, the study subjects achieved higher completion rates (80%) than that reported for three similar exercise intervention trials (70%, 77%, and 78%, respectively) ([@b14-jer-14-5-891]; [@b30-jer-14-5-891]) and less than the rate (81%) reported by another study ([@b11-jer-14-5-891]). This may also be as a result of some musculoskeletal symptomatic relief such as reduced pain at the muscle and joints, and improved endurance as was reported by the subjects during the first two weeks of the exercise program may have motivated them to adhere to the exercise program.

There was an improvement (decrease) in cardiovascular parameters (SBP, DBP, HR) in the control group, though it did not attain significance. However, there was also a significant improvement (decrease) in cardiovascular parameters in the experimental group. There was also a significant improvement (decrease) in the cardiovascular parameters between the control and experimental group. This shows an improved cardiovascular fitness resulting from both supervised (intervention) and nutritional program. The result is in line with a similar findings of improved cardiovascular fitness, evidenced in the resting heart of 20 bpm difference between the supervised aerobic and resistance exercise group and the unsupervised walking program ([@b8-jer-14-5-891]), and another study in brazil by [@b28-jer-14-5-891] showing a significant change (decrease) in resting HR of intervention group using aerobic and resistance exercise training in HIV subjects. This is encouraging since impaired physical endurance is frequently observed in this population.

Furthermore, cardiorespiratory fitness (VO~2max~) improved significantly in the experimental group compared to the control group. This is in agreement with the findings of [@b24-jer-14-5-891], using functional capacity to predict VO~2max~ after a Shuttle test. There was an improvement of VO~2max~ in the intervention group compared to the control group. The improved VO~2max~ is an important measure of aerobic capacity related to health and longevity ([@b23-jer-14-5-891]; [@b25-jer-14-5-891]). HIV individuals may have up to 9% lower VO~2max~ values, compared to age-matched healthy individuals ([@b18-jer-14-5-891]). In contrast to the above results, others have found nonsignificant 9%--10% increases in VO~2max~ following a combined training protocol after 12 and 16 weeks in HIV infected individuals ([@b29-jer-14-5-891]).

More so, within group analysis of body composition parameters showed a significant improvement (decrease) in the body composition parameters (WC, BMI, body and muscle mass) (*P*\<0.05) in the experimental group. Body composition parameters also improved significantly between groups (*P*\<0.05). VF showed no significant change within group but significantly decreased when compared between group (*P*=0.001). Since HIV-infected individuals receiving HAART are at risk for greater fat (subcutaneous and visceral) accumulation which may positively influence WC, they represent a population at greater risk for metabolic abnormalities linked to cardiovascular disease and diabetes. Therefore, the reductions in WC and percentage BF were significant in the experimental group and may be a marker for decreased risk of metabolic diseases associated with abdominal obesity. The result is agreement with the result from [@b28-jer-14-5-891] who found a significant decrease in both BMI, BF, and muscle mass (increase) in a study to evaluate the impact of regular physical activity on HIV patients. [@b11-jer-14-5-891] in a similar study of longer duration (6 months) reported a significant increase in muscle area (6±1 cm^2^ vs. 2±1 cm^2^, *P*=0.02) and WC (decrease) compared with the control group.

In addition to negative physical and physiological changes, HIV-infected patients receiving HAART can also experience psychological responses such as agitation, confusion, anxiety, nightmares, mania, and depression. The experimental and control groups showed significant increase in the QoL scores. This significance exists both within and between groups, but the change is more in the experimental group. The experimental subjects reported substantial improvements in both physical and mental QoL scales (55 points and 48 points, respectively) while the control subjects had lower scores on the same scales (27 points and 33points, respectively). This indicates that the subjects reported improvements in performing daily activities such as bathing, dressing, walking, climbing stairs, and carrying groceries, which are activities captured in the physical QoL scale.

Furthermore, higher mental QoL scores observed in the experimental group indicate improved mental health with aerobic exercise and lower risk of depression ([@b35-jer-14-5-891]). This result strongly agree with the findings of [@b28-jer-14-5-891] in a related study which revealed a marked improvement in QoL domains both in the exercise and nonexercise group. [@b8-jer-14-5-891] and [@b11-jer-14-5-891] also found that QoL domain improved significantly in HIV subjects using exercise intervention.

It is of importance to remark that from the result of this study all subjects received a clear benefit in terms of QoL evaluation, even those who were assigned to counseling sessions only. This fact suggests that the simple participation in an educational activity can promote a significant increase in QoL of patients with HIV/AIDS. A 6-week aerobic exercise intervention coupled with nutritional guidance in people living with HIV/AIDS was able to significantly improve cardiovascular fitness, body composition and QoL. Nutritional counseling alone can bring about an improvement only in QoL in people living with HIV/AIDS.

Future trials should focus upon longer duration exercise programs for enhancing the general health status of individuals. It would be relevant to specifically target HIV patients of lower socio economic status, since they represent individuals with greater susceptibility to disease progression and premature mortality ([@b9-jer-14-5-891]). Studies with follow-up for longer duration is required to define the duration of such effects and the need of a periodical "booster" to keep the benefits over time. It is important to include supervised exercise as a routine in HIV/AIDS clinics. Physiotherapist should be involved in HIV/AIDS intervention programs for supervised exercise programs and management of other musculoskeletal impairment.
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###### 

Demographic data of control and experimental group

  Variable              Control     Intervention
  --------------------- ----------- --------------
  Age (yr)              40.9±8      41±7.8
                                    
  Gender                            
   Male                 11 (40.7)   8 (32.0)
   Female               16 (59.3)   17 (68.0)
   Ratio, male:female   1:1.5       1:2.1
                                    
  Marital status                    
   Single               10 (37.0)   7 (28.0)
   Married              17 (63.0)   18 (72.0)
                                    
  Educational level                 
   Primary              0 (0)       0 (0)
   Secondary            16 (59.3)   18 (72.0)
   Tertiary             11 (40.7)   7 (28.0)
                                    
  Height (m)            1.62±0.74   1.6±0.09

Values are presented as mean±standard deviation or number (%).

###### 

Between group comparison of cardiovascular parameters

  Variable      Study group (n=30)   Control group (n=28)   *t*-value   *P*-value
  ------------- -------------------- ---------------------- ----------- ----------------------------------------------------
  Pre                                                                   
   SBP          123±15.78            125±15.67              −5.525      0.661
   DBP          77±10.52             78.9±10.49             −3.280      0.701
   HR           77.6±10.79           78.97±10.83            −2.423      0.164
   VO~2max~     41.4±5.73            40.5±4.17              0.643       0.525
                                                                        
  Post                                                                  
   SBP (mmHg)   77.47±13.38          124.20±14.54           −7.888      0.001[\*](#tfn4-jer-14-5-891){ref-type="table-fn"}
   DBP (mmHg)   71.3±6.11            77.7±9.79              −7.055      0.001[\*](#tfn4-jer-14-5-891){ref-type="table-fn"}
   HR (bpm)     72.40±6.63           78.03±10.01            −6.055      0.001[\*](#tfn4-jer-14-5-891){ref-type="table-fn"}
   VO~2max~     65±9.05              40.60±4.24             12.75       0.001[\*](#tfn4-jer-14-5-891){ref-type="table-fn"}

Values are presented as mean±standard deviation.

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; VO~2max~, maximum oxygen consumption.

Significance between groups at *P*\<0.05.

###### 

Within group comparison of cardiovascular parameters

  Variable        Pre         Post        *t*-value   *P*-value
  --------------- ----------- ----------- ----------- ----------------------------------------------------
  Study group                                         
   SBP (mmHg)     123±15.79   117±13.36   6.378       0.001[\*](#tfn7-jer-14-5-891){ref-type="table-fn"}
   DBP (mmHg)     76±10.77    71±6.10     5.051       0.001[\*](#tfn7-jer-14-5-891){ref-type="table-fn"}
   HR (bpm)       78±11.29    72±6.63     4.716       0.001[\*](#tfn7-jer-14-5-891){ref-type="table-fn"}
   VO~2max~       41.4±5.73   65±9.05     −20.376     0.001[\*](#tfn7-jer-14-5-891){ref-type="table-fn"}
                                                      
  Control group                                       
   SBP (mmHg)     125±15.39   124±14.54   4.350       0.062
   DBP (mmHg)     79±10.50    78±9.79     3.714       0.0781
   HR (bpm)       79±10.83    78±10       3.080       0.124
   VO~2max~       40±4.17     40.6±4.24   −0.279      0.782

Values are presented as mean±standard deviation.

SBP, systolic blood pressure; DBP, diastolic blood pressure; HR, heart rate; VO~2max~, maximum oxygen consumption.

Significance within group at *P*\<0.05.

###### 

Between group comparison of body composition parameters

  Variable         Study group (n=30)   Control group (n=28)   *t*-value   *P*-value
  ---------------- -------------------- ---------------------- ----------- -----------------------------------------------------
  Pre                                                                      
   BMI (kg/m^2^)   27.39±4.25           27.35±5.10             0.039       0.969
   BF (%)          30.52±10.56          30.92±9.92             −0.399      0.693
   VF (%)          6.9±1.61             7.93±1.64              −2.079      0.047[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}
   WC (cm)         82.53±8.58           81.5±8.58              0.444       0.661
   Muscle (%)      30.45±6.87           29.95±6.59             0.280       0.781
                                                                           
  Post                                                                     
   BMI (kg/m^2^)   23.37±3.55           27.2±5.10              0.997       0.002[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}
   BF (%)          27±10                30.6±10.10             −4.053      0.042[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}
   VF (%)          6±1.37               7.59±1.68              −3.763      0.001[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}
   WC (cm)         77.1±6.59            81.27±8.49             −3.663      0.002[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}
   Muscle (%)      31.75±6.46           29.59±6.47             2.460       0.001[\*](#tfn10-jer-14-5-891){ref-type="table-fn"}

Values are presented as mean±standard deviation.

BMI, body mass index; BF, body fat; VF, visceral fat; WC, waist circumference.

Significance between groups at *P*\<0.05.

###### 

Within group comparison of body composition parameters

  Variable         Pre          Post         *t*-test   *P*-value
  ---------------- ------------ ------------ ---------- -----------------------------------------------------
  Study group                                           
   BMI (kg/m^2^)   27.39±4.25   23.37±5.55   4.502      0.001[\*](#tfn13-jer-14-5-891){ref-type="table-fn"}
   WC (cm)         82.5±8.58    77.1±6.59    6.168      0.001[\*](#tfn13-jer-14-5-891){ref-type="table-fn"}
   VF (%)          6.9±1.61     6±1.37       −7.801     0.701
   BF (%)          30.5±6.87    27±10        6.400      0.001[\*](#tfn13-jer-14-5-891){ref-type="table-fn"}
   Muscle (%)      30.4±6.87    34.75±4.02   −6.196     0.001[\*](#tfn13-jer-14-5-891){ref-type="table-fn"}
                                                        
  Control group                                         
   BMI (kg/m^2^)   27.3±5.08    27.2±5.10    0.096      0.960
   WC (cm)         81.5±8.53    81.27±8.49   1.523      0.961
   VF (%)          7.93±1.64    7.59±1.68    0.208      0.680
   BF (%)          30.92±9.92   30.6±10      1.494      0.680
   Muscle (%)      29.95±6.59   29.76±6.50   0.417      0.680

Values are presented as mean±standard deviation.

BMI, body mass index; BF, body fat; VF, visceral fat; WC, waist circumference.

Significance within group at *P*\<0.05.

###### 

Between group comparison of quality of life scores

  Variable                 Study group (n=30)   Control group (n=28)   *t*-value   *P*-value
  ------------------------ -------------------- ---------------------- ----------- -----------------------------------------------------
  Pre                                                                              
   General health          26.17±5.68           21.17±6.11             −0.612      0.545
   Physical functioning    38.97±4.97           40.1±5.33              −2.152      0.060
   Role functioning        20±24.90             25±25.43               −0.828      0.415
   Cognitive functioning   42.7±17.90           34.83±9.10             1.932       0.063
   Mental health           23.77±11.33          27.33±11.43            −1.426      0.164
   Energy/vitality         26.67±5.46           29.5±8.13              −1.598      0.121
                                                                                   
  Post                                                                             
   General health          51.33±3.93           35±5.41                13.927      0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}
   Physical functioning    92.47±6.45           67.1±9.00              12.868      0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}
   Role functioning        73.33±31.44          41.67 ±32.37           3.898       0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}
   Cognitive functioning   100±0.00             72.67±8.17             18.320      0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}
   Mental health           71.37±3.71           60.37±6.67             9.090       0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}
   Energy/vitality         59.67±4.72           47±7.38                8.382       0.001[\*](#tfn15-jer-14-5-891){ref-type="table-fn"}

Values are presented as mean±standard deviation.

Significance within group at *P*\<0.05.

###### 

Within group comparison of quality of life scores

  Variable                 Pre          Post         *t*-value   *P*-value
  ------------------------ ------------ ------------ ----------- -----------------------------------------------------
  Study group                                                    
   General health          26.2±5.68    51.3±3.93    −20.796     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Physical functioning    37.3±4.98    92.5±6.45    −55.559     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Role functioning        20±24.91     73±31.44     −7.899      0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Cognitive functioning   42.7±17.90   100±00       −17.523     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Mental health           23.8±11.30   71.4±3.71    −21.682     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Energy/vitality         26.7±5.47    59.7±4.72    −26.690     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
                                                                 
  Control group                                                  
   General health          27.2±6.10    35±5.41      −6.861      0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Physical functioning    40 ±5.33     67±9.03      −14.628     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Role functioning        25±25.43     41.7±32.39   −3.340      0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Cognitive functioning   34.8±9.05    72.67±8.17   −19.776     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Mental health           27±11.43     60.4±6.67    −16.938     0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}
   Energy/vitality         29.5±8.10    47±7.38      8.5558      0.001[\*](#tfn17-jer-14-5-891){ref-type="table-fn"}

Values are presented as mean±standard deviation.

Significance within group at *P*\<0.05.
